Scarica l'app Stockscreener
110.19
0.51%
-0.57
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché HALO Giù?
Forum
Previsione
Precedente Chiudi:
$110.76
Aprire:
$109.91
Volume 24 ore:
956.34K
Relative Volume:
0.48
Capitalizzazione di mercato:
$12.51B
Reddito:
$1.51B
Utile/perdita netta:
$348.84M
Rapporto P/E:
39.63
EPS:
2.7805
Flusso di cassa netto:
$667.65M
1 W Prestazione:
+4.59%
1M Prestazione:
+32.39%
6M Prestazione:
+57.37%
1 anno Prestazione:
+50.12%
Intervallo 1D:
$109.00
$111.15
Intervallo di 1 settimana:
$103.47
$111.15
Portata 52W:
$61.23
$111.15
Halozyme Therapeutics Inc Stock (HALO) Company Profile
Nome
Halozyme Therapeutics Inc
Settore
Industria
Telefono
(858) 794-8889
Indirizzo
12390 EL CAMINO REAL, SAN DIEGO, CA
Compare HALO vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HALO
Halozyme Therapeutics Inc
|
110.19 | 12.04B | 1.51B | 348.84M | 667.65M | 2.7805 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-04 | Downgrade | Goldman | Neutral → Sell |
| 2025-10-14 | Aggiornamento | Leerink Partners | Underperform → Market Perform |
| 2025-08-06 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-10 | Ripresa | Goldman | Neutral |
| 2025-05-14 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | Downgrade | Leerink Partners | Market Perform → Underperform |
| 2024-10-07 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-09-19 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-06-07 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2024-02-29 | Iniziato | TD Cowen | Outperform |
| 2023-07-24 | Downgrade | Goldman | Buy → Neutral |
| 2023-07-24 | Iniziato | H.C. Wainwright | Buy |
| 2023-05-10 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | Ripresa | Berenberg | Buy |
| 2023-03-16 | Downgrade | SVB Securities | Outperform → Market Perform |
| 2022-12-21 | Ripresa | Morgan Stanley | Overweight |
| 2022-11-28 | Iniziato | Wells Fargo | Overweight |
| 2022-09-09 | Iniziato | Morgan Stanley | Overweight |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2021-06-14 | Iniziato | Evercore ISI | Outperform |
| 2021-05-17 | Iniziato | SVB Leerink | Outperform |
| 2021-05-11 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-01-21 | Reiterato | The Benchmark Company | Buy |
| 2020-12-17 | Iniziato | Berenberg | Buy |
| 2020-09-14 | Ripresa | JP Morgan | Overweight |
| 2020-07-01 | Iniziato | The Benchmark Company | Buy |
| 2020-02-05 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2020-01-09 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2020-01-08 | Iniziato | Goldman | Buy |
| 2019-11-05 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2018-10-19 | Ripresa | Piper Jaffray | Neutral |
| 2018-05-11 | Downgrade | Barclays | Equal Weight → Underweight |
| 2018-01-24 | Iniziato | Goldman | Neutral |
| 2017-10-16 | Reiterato | Piper Jaffray | Overweight |
| 2017-01-06 | Downgrade | Citigroup | Buy → Neutral |
| 2016-11-03 | Iniziato | Deutsche Bank | Buy |
| 2015-12-04 | Iniziato | Wells Fargo | Outperform |
| 2015-11-18 | Iniziato | Citigroup | Buy |
| 2015-09-22 | Iniziato | Barclays | Overweight |
| 2015-06-22 | Reiterato | JP Morgan | Overweight |
| 2015-03-03 | Reiterato | UBS | Buy |
| 2015-02-18 | Reiterato | MLV & Co | Buy |
| 2015-01-08 | Reiterato | MLV & Co | Buy |
Mostra tutto
Halozyme Therapeutics Inc Borsa (HALO) Ultime notizie
New Halozyme (NASDAQ: HALO) director logs zero stock in first ownership filing - Stock Titan
HALO Stock Rises 36% in a Month: Here's What You Should Know - TradingView
Great Lakes Advisors LLC Purchases Shares of 36,039 Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics (HALO) Adds A New Director, Is It 21% Overvalued? - Sahm
Aurora Investment Counsel Takes Position in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme CEO Helen Torley sells $6.28m in company shares By Investing.com - Investing.com Australia
Halozyme CEO Helen Torley sells $6.28m in company shares - Investing.com
Halozyme Therapeutics (NASDAQ:HALO) CEO Sells 20,000 Shares of Stock - MarketBeat
Halozyme (NASDAQ: HALO) CEO sells tens of thousands of shares - Stock Titan
Halozyme (HALO) Levels: Moves 2.60% Up to $107.62 in the Latest Reading; Range View: Price Remains Between $102.24 Support and $113.00 Resistance for the Current SessionInsider Buying Alerts - Vinanet
Halozyme Appoints Dannielle Appelhans to Board of Directors - The Globe and Mail
Foster & Motley Inc. Invests $2 Million in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Diversify Advisory Services LLC Invests $2.77 Million in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics Appoints Dannielle Appelhans to Board of Directors - Kalkine Media
Halozyme Therapeutics (NASDAQ:HALO): What Is Driving the Rally? - Kalkine Media
Halozyme adds Dannielle Appelhans to board of directors - Investing.com
Halozyme adds Dannielle Appelhans to board of directors By Investing.com - Investing.com Australia
Halozyme Therapeutics stock hits all-time high of 104.86 USD By Investing.com - Investing.com Australia
Halozyme Appoints Dannielle Appelhans to its Board of Directors - PR Newswire
Halozyme Therapeutics (NASDAQ:HALO) Reaches New 52-Week HighWhat's Next? - MarketBeat
Halozyme Therapeutics stock hits all-time high of 104.86 USD - Investing.com
H.C. Wainwright reiterates Halozyme stock rating on partner data By Investing.com - Investing.com Canada
HALO Q2 2026 Earnings: EPS Surges 21.75% Above Estimates, Shares Climb 4.4%New Analyst Coverage - Vinanet
Halozyme (NASDAQ: HALO) insider lines up new stock sale after recent disposals - Stock Titan
H.C. Wainwright Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $115 - Moomoo
Horizon Investment Services LLC Buys Shares of 28,793 Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics, Inc. (HALO) Stock Analysis: A Biotech Powerhouse with Robust Revenue Growth - DirectorsTalk Interviews
Chase Investment Counsel Corp Buys New Stake in Halozyme Therapeutics, Inc. $HALO - MarketBeat
HALO|Halozyme Therapeutics Inc|Price:104.890|Chg%:+1.890 - TradingKey
The Top 5 Analyst Questions From Halozyme Therapeutics’s Q2 Earnings Call - Yahoo Finance
Incyte Corporation (INCY) has the Bigger Revenue Base, but Could Halozyme Therapeutics, Inc. (HALO) have the Better Economics? - Yahoo Finance
Halozyme (HALO) Q2 2026 Earnings Call Transcript - The Globe and Mail
Halozyme Therapeutics (HALO) is an Incredible Growth Stock: 3 Reasons Why - Yahoo Finance
Is Halozyme Therapeutics (HALO) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Halozyme Therapeutics, Inc. (HALO) Stock Forecasts - Yahoo Finance
Wedge Capital Management L L P NC Invests $31.61 Million in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Handelsbanken Fonder AB Grows Stake in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) Sets New 52-Week HighHere's What Happened - MarketBeat
Halozyme Therapeutics, Inc. (HALO) stock price, news, quote and history - Yahoo Finance Australia
Halozyme Therapeutics (HALO) Director Bernadette Connaughton Sel - GuruFocus
Halozyme director Connaughton sells $167,152 in shares By Investing.com - Investing.com Nigeria
Insider Selling: Halozyme Therapeutics (NASDAQ:HALO) Director Sells $167,152.80 in Stock - MarketBeat
Halozyme director Connaughton sells $167,152 in shares - Investing.com
Halozyme Therapeutics (HALO) affiliate plans stock option-related share sales in Form 144 - Stock Titan
Halozyme Therapeutics (HALO) director sells 1,626 shares in Rule 10b5-1 plan trade - Stock Titan
HALO Q2 Deep Dive: Royalty Diversification and New Pipeline Drive Upgraded Guidance - Yahoo Finance
What Halozyme Therapeutics (HALO) Guidance Raise Means For Valuation - Sahm
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Halozyme Therapeutics (HALO) Shares Skyrocket, What You Need To Know - Yahoo Finance
Halozyme Therapeutics (HALO) insider schedules 1,626-share stock sale via trading plan - Stock Titan
Halozyme Therapeutics (HALO) Is Up 24.9% After Record Q2, Higher 2026 Guidance And New ENHANZE DealsHas The Bull Case Changed? - Sahm
Halozyme Therapeutics Inc Azioni (HALO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Halozyme Therapeutics Inc Azioni (HALO) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Torley Helen | PRESIDENT AND CEO |
Aug 18 '26 |
Option Exercise |
18.41 |
20,000 |
368,200 |
787,780 |
| Torley Helen | PRESIDENT AND CEO |
Aug 19 '26 |
Option Exercise |
18.41 |
20,000 |
368,200 |
787,780 |
| Torley Helen | PRESIDENT AND CEO |
Aug 19 '26 |
Sale |
107.00 |
20,000 |
2,139,976 |
767,780 |
| Torley Helen | PRESIDENT AND CEO |
Aug 18 '26 |
Sale |
104.18 |
20,000 |
2,083,525 |
767,780 |
| Torley Helen | PRESIDENT AND CEO |
Aug 17 '26 |
Sale |
102.60 |
20,000 |
2,052,091 |
767,780 |
0.86%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):